"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Singapore, April 1 -- Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions. The company is well poised to enable local development and manufacturing in India to drive affordable and accessible CGTs by academia and industry for Indian as well as global patients. In conversation with BioSpectrum Asia, Dr Boris Stoffel, Chief Executive Officer and Managing Director of Miltenyi Biotec, talks about the real challenges associated with the use of CGT, and the way forward.
Could you elaborate on the narrative behind Miltenyi Biotec's invention of the groundbreaking...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.